產品屬性：
產品名稱 | Olsalazine-13C6 |
規格 | 1 mg |
貨號 | EY-01Y17137 |
Cas No.: N/A
別名: N/A
化學名: N/A
分子式: C8[13C]6H10N2O6
分子量: 308.2
溶解度: DMSO: soluble,Methanol: soluble
儲存條件: -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產品描述：
Olsalazine-13C6 is intended for use as an internal standard for the quantification of olsalazine by GC- or LC-MS. Olsalazine is an orally bioavailable prodrug form of the anti-inflammatory agent 5-aminosalicylic acid that is cleaved by bacterial azo reductases in the gut to generate active 5-ASA.1 In vitro, olsalazine increases ion transport in isolated rabbit distal ileum when applied to the luminal side (ED50 = 0.3 mM) and stimulates fluid transport in rat jejunum when used at a concentration of 5 mM.2,3 Olsalazine (150 mg/kg for 8 days) improves stool consistency and decreases occult and gross bleeding as well as myeloperoxidase (MPO) activity and leukotriene B4 levels in colon tissue in a mouse model of acute colitis induced by dextran sulfate .4 Olsalazine also inhibits bovine xanthine oxidase in vitro (IC50 = 3.4 mg/L) and lowers serum uric acid levels in a mouse model of hyperuricemia induced by oxonic acid when administered at a dose of 20 mg/kg.5 Formulations containing olsalazine have been used in the treatment of inflammatory bowel disease (IBD) and ulcerative colitis.1.Nugent, S.G., Kumar, D., Rampton, D.S., et al.Intestinal luminal pH in inflammatory bowel disease: Possible determinants and implications for therapy with aminosalicylates and other drugsGut48(4)571-577(2001)
2.Pamukcu, R., Hanauer, S.B., and Chang, E.B.Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acidGastroenterology95(4)975-981(1988)
3.Mohsen, A.Q.M., Mulvey, D., Priddle, J.D., et al.Effects of olsalazine in the jejunum of the ratGut28(3)346-352(1987)
4.Murthy, S., Murthy, N.S., Coppola, D., et al.The efficacy of BAY y 1015 in dextran sulfate model of mouse colitisInflamm. Res.46(6)224-233(1997)
5.Niu, Y., Li, H., Gao, L., et al.Old drug, new indication: Olsalazine sodium reduced serum uric acid levels in mice via inhibiting xanthine oxidoreductase activityJ. Pharmacol. Sci.135(3)114-120(2017)
特別提醒公司產品僅供科研使用
